Efficacy of Vinblastine and Prednisone in Multicentric Reticulohistiocytosis With Onset in Infancy.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: American Academy of Pediatrics Country of Publication: United States NLM ID: 0376422 Publication Model: Print Cited Medium: Internet ISSN: 1098-4275 (Electronic) Linking ISSN: 00314005 NLM ISO Abbreviation: Pediatrics Subsets: MEDLINE
    • Publication Information:
      Publication: Elk Grove Village Il : American Academy of Pediatrics
      Original Publication: Springfield, Ill., Thomas.
    • Subject Terms:
      Antineoplastic Agents, Phytogenic/*therapeutic use ; Glucocorticoids/*therapeutic use ; Histiocytosis, Non-Langerhans-Cell/*drug therapy ; Prednisone/*therapeutic use ; Skin/*pathology ; Vinblastine/*therapeutic use; Age of Onset ; Child, Preschool ; Drug Therapy, Combination ; Female ; Hand/diagnostic imaging ; Histiocytosis, Non-Langerhans-Cell/diagnosis ; Histiocytosis, Non-Langerhans-Cell/pathology ; Humans
    • Abstract:
      Multicentric reticulohistiocytosis (MRH) is a rare histiocytic proliferative disorder of uncertain etiology, characterized by mucocutaneous papulonodular lesions and progressive, symmetric erosive arthritis. MRH can coexist with various autoimmune disorders, tuberculosis, and malignancy. It usually occurs in the elderly and is very rare in children. This is probably the first case in which disease manifestation appeared in infancy in the form of skin lesions. The patient had recurrent ulceration of cutaneous lesions, which is unusual in MRH. Early diagnosis and aggressive treatment are essential to prevent progressive irreversible course and development of arthritis mutilans. Various drugs, such as steroids, nonsteroidal anti-inflammatory drugs, immunosuppressants, interleukin inhibitors, and tumor necrosis factor-α antagonist, have been tried with variable responses. The present case responded well to vinblastine and steroid, which have not been reported previously. Here, we document a case of MRH with early onset in infancy along with role of vinblastine and prednisone in its treatment.
      (Copyright © 2016 by the American Academy of Pediatrics.)
    • Accession Number:
      0 (Antineoplastic Agents, Phytogenic)
      0 (Glucocorticoids)
      5V9KLZ54CY (Vinblastine)
      VB0R961HZT (Prednisone)
    • Publication Date:
      Date Created: 20160521 Date Completed: 20170615 Latest Revision: 20180606
    • Publication Date:
      20221213
    • Accession Number:
      10.1542/peds.2015-2118
    • Accession Number:
      27199388